Oral enzyme therapy improves remission time, soluble TNF-receptors and b2-microglobulin concentration in chemotherapy treated multiple myeloma patients

Desser L.¹, Sakalova A.², Zavadova E.¹, Holomanova D.², Mohr T.¹

1 Institute of Tumorbiology / Cancer Research, Dpt. Applied and Experimental Oncology, University of Vienna, Austria
² Clinic of Haematology and Transfusiology, University of Bratislava, Slovakia

7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva, Switzerland. 19-21 May, 97 - published in Inter. Journal of  Tissue Reactions Vol. XIX, No. 1/2, pp. 94, 1997 - Abst. 116 - ISSN 0250-0868

149K/245 (19-04-2) 

We determined the soluble TNF-Receptors (sTNF-R) p55 and p75, b2-Microglobulin(b2M), Interleukin6 (IL-6) and Tumor Necrosis Factor (TNF) in the sera of 198 patients with Multiple Myeloma (MM) stage I to III, before therapy, after chemotherapy (MOCCANMCP), or after enzyme-(Wobe-Mugos) + chemotherapy, and in 67 healthy volunteers. The remission time of MM patients after chemotherapy and after enzyme- + chemotherapy were compared retrospectively.

Results

The remission time was significantly (p<0.001 ) longer in the enzyme treated patients stage 11. The serum concentrations of sTNF-R and b2M were significantly (p<0.05) elevated in patients stage II and III before therapy. sTNF-R and b2M correlate with each other. The levels of the serum markers sTNF-R p55, sTNF-R p75, and b2M were lower after chemotherapy and significantly lower after enzyme- + chemotherapy. During the time course over 17 months the levels of b2M, p55 and p75 in 52 MM patients stage II (chemo- or enzyme- + chemotherapy) were compared. A significant reduction of these marker concentrations in MM patients treated with enzyme- + chemotherapy (p<0.001 ) as compared with the chemotherapy group was observed. No differences in IL-6 concentrations were detected between the treatment groups.

Conclusion: Treatment with Wobe-Mugos® in addition to conventional chemotherapy prolongs remission times in stage II MM patients and reduces the concentrations of progression markers.

Full text published in Int. J. Immunotherapy 1997, Vol. XIII, No. 3/4, pp 121 - 130;  SO 112 (19-04-2)